Alvotech Completes FDA Surveillance Inspection, Remains on Track for BLA Resubmissions
核心洞察
Alvotech's Reykjavik manufacturing facility successfully completed a routine FDA cGMP surveillance inspection on May 8, 2026, receiving a Form 483 with observations the company believes can be addressed quickly.
The biotechnology company remains well positioned to resubmit relevant Biologics License Applications in the second quarter of 2026, with FDA approval expected during 2026.
The inspection outcome demonstrates strong cGMP fundamentals and validates the robustness of improvements implemented since last year at the biosimilar manufacturing site.
Alvotech announced that the U.S. Food and Drug Administration has completed a routine cGMP surveillance inspection of the company's manufacturing facility in Reykjavik, Iceland, positioning the biosimilar developer to move forward with planned regulatory resubmissions in the second quarter of 2026.
The inspection concluded on May 8, 2026, with the FDA issuing a Form 483. Alvotech believes the observations identified can be addressed quickly and do not raise substantial issues with the site or its operations.
Regulatory Path Forward
Based on the inspection outcome, Alvotech is well positioned to resubmit the relevant Biologics License Applications this quarter once final data compilation is complete. The company continues to expect FDA approval for the relevant BLAs during 2026.
The company views the inspection results as validation of the strong cGMP fundamentals at the site and the robustness of improvements implemented since last year. This regulatory milestone represents a critical step in Alvotech's path to expanding its biosimilar portfolio in the U.S. market.
Established Biosimilar Portfolio
Alvotech has already established a significant presence in the biosimilar market with five products approved and marketed across multiple global markets. The company's current commercial portfolio includes biosimilars to major reference biologics: Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab).
The biotechnology company's development pipeline includes nine disclosed biosimilar candidates targeting diverse therapeutic areas including autoimmune disorders (搜索), eye disorders (搜索), osteoporosis (搜索), respiratory disease (搜索), and cancer (搜索).
Global Commercial Strategy
Founded by Robert Wessman, Alvotech focuses exclusively on biosimilar development and manufacturing, seeking to become a global leader through high-quality, cost-effective products enabled by a fully integrated approach and broad in-house capabilities.
The company has established a network of strategic commercial partnerships to provide global reach and leverage local expertise across key markets including the United States, Europe, Japan, China, other Asian countries, and large parts of South America, Africa, and the Middle East.